346 related articles for article (PubMed ID: 28958389)
1. JARID1 Histone Demethylases: Emerging Targets in Cancer.
Harmeyer KM; Facompre ND; Herlyn M; Basu D
Trends Cancer; 2017 Oct; 3(10):713-725. PubMed ID: 28958389
[TBL] [Abstract][Full Text] [Related]
2. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
3. JARID1/KDM5 demethylases as cancer targets?
Taylor-Papadimitriou J; Burchell J
Expert Opin Ther Targets; 2017 Jan; 21(1):5-7. PubMed ID: 27882807
[No Abstract] [Full Text] [Related]
4. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
5. Jumonji histone demethylases as emerging therapeutic targets.
Park SY; Park JW; Chun YS
Pharmacol Res; 2016 Mar; 105():146-51. PubMed ID: 26816087
[TBL] [Abstract][Full Text] [Related]
6. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
Molecules; 2019 May; 24(9):. PubMed ID: 31060229
[No Abstract] [Full Text] [Related]
8. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B; Kidder BL
Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
[TBL] [Abstract][Full Text] [Related]
9. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
Chin YW; Han SY
Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
[TBL] [Abstract][Full Text] [Related]
10. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
11. JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
Tobin SJ; Chang H; Kent MS; Davies AE
Vet Comp Oncol; 2021 Sep; 19(3):518-528. PubMed ID: 33715247
[TBL] [Abstract][Full Text] [Related]
12. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
Sayegh J; Cao J; Zou MR; Morales A; Blair LP; Norcia M; Hoyer D; Tackett AJ; Merkel JS; Yan Q
J Biol Chem; 2013 Mar; 288(13):9408-17. PubMed ID: 23408432
[TBL] [Abstract][Full Text] [Related]
13. KdmB, a Jumonji Histone H3 Demethylase, Regulates Genome-Wide H3K4 Trimethylation and Is Required for Normal Induction of Secondary Metabolism in Aspergillus nidulans.
Gacek-Matthews A; Berger H; Sasaki T; Wittstein K; Gruber C; Lewis ZA; Strauss J
PLoS Genet; 2016 Aug; 12(8):e1006222. PubMed ID: 27548260
[TBL] [Abstract][Full Text] [Related]
14. KDM5 lysine demethylases are involved in maintenance of 3'UTR length.
Blair LP; Liu Z; Labitigan RL; Wu L; Zheng D; Xia Z; Pearson EL; Nazeer FI; Cao J; Lang SM; Rines RJ; Mackintosh SG; Moore CL; Li W; Tian B; Tackett AJ; Yan Q
Sci Adv; 2016 Nov; 2(11):e1501662. PubMed ID: 28138513
[TBL] [Abstract][Full Text] [Related]
15. Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview.
McCann TS; Sobral LM; Self C; Hsieh J; Sechler M; Jedlicka P
Expert Opin Ther Targets; 2019 Apr; 23(4):267-280. PubMed ID: 30759030
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
Kuźbicki Ł; Lange D; Stanek-Widera A; Chwirot BW
BMC Cancer; 2017 Dec; 17(1):854. PubMed ID: 29246117
[TBL] [Abstract][Full Text] [Related]
17. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
Li Q; Shi L; Gui B; Yu W; Wang J; Zhang D; Han X; Yao Z; Shang Y
Cancer Res; 2011 Nov; 71(21):6899-908. PubMed ID: 21937684
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
Denis H; Van Grembergen O; Delatte B; Dedeurwaerder S; Putmans P; Calonne E; Rothé F; Sotiriou C; Fuks F; Deplus R
Mol Biosyst; 2016 Feb; 12(2):404-13. PubMed ID: 26621457
[TBL] [Abstract][Full Text] [Related]
19. Advances in histone demethylase KDM4 as cancer therapeutic targets.
Lee DH; Kim GW; Jeon YH; Yoo J; Lee SW; Kwon SH
FASEB J; 2020 Mar; 34(3):3461-3484. PubMed ID: 31961018
[TBL] [Abstract][Full Text] [Related]
20. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]